AstraZeneca, Biovail enter into agreement for Zoladex

Share this article:
AstraZeneca and Biovail have entered into an agreement in which Biovail's specialty sales force will promote AstraZeneca's Zoladex (goserelin acetate implant) to obstetricians and gynecologists for the treatment of endometriosis in the US and Puerto Rico. Financial terms of the deal were not disclosed. Biovail's 85-member specialty sales force currently promotes Zovirax cream and ointment to specialists and selected primary-care physicians in the US. 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions